# P1 V7 Final Status Report — 11 January 2026

**Version:** V7 (Canonical JCIM Submission)  
**Status:** ✅ **READY FOR SUBMISSION**  
**Last Major Update:** 2026-01-11 21:00 (All 5 ORCID iDs collected)

---

## Executive Summary

V7 is the **canonical submission version** for JCIM, superseding V6 (10 August 2026). All technical requirements are met:
- ✅ Main manuscript: 25 pages, 0 compilation errors
- ✅ Supporting Information: 17 pages, 0 compilation errors  
- ✅ Comprehensive validation documentation (DEKOIS, MMV, redocking)
- ✅ Physicochemical characterization tables
- ✅ **MPO and DiffDock mathematical framework documented (NEW 11 Jan 2026)**
- ✅ Enhanced narrative quality (scientific prose, anti-AI patterns eliminated)
- ✅ Methodological rigor (grid specifications, efficiency documentation)
- ✅ **ALL 5 ORCID iDs collected and verified** (NEW 11 Jan 2026 21:00)
- ✅ **Funding acknowledgment added** ("No external funding was received")

**Remaining Requirements:** NONE - ✅ **FULLY READY FOR SUBMISSION**

---

## Today's Achievements (11 January 2026)

### Phase 1: V5 Integration (Validation Documentation)
**Status:** ✅ Complete  
**Added:** 3 validation tables + SM Section S11 (renumbered to S12 after S10 addition)

### Phase 2: V7 Promotion to Canonical Version
**Status:** ✅ Complete  
**Updated:** AGENTS.md, submission package created, documentation complete

### Phase 3: Pre-Submission Requirements
**Status:** ✅ **COMPLETE (including ALL ORCIDs 21:00)**  
**Added:** Cover letter (refined 19:56), ORCID instructions updated with all 5 ORCIDs, funding acknowledgment

### Phase 4: MPO and DiffDock Integration (Option 3)
**Status:** ✅ **COMPLETE** (TODAY'S WORK)  
**Added:** New SM Section S10 with 7 mathematical equations + rationale

---

## Final Manuscript Specifications

### Main Manuscript
- **File:** `P1_V7_Integrated_Polypharmacology_RRS.pdf`
- **Pages:** 25
- **Size:** 449 KB
- **Sections:** Abstract, Introduction, Materials & Methods, Results (6 subsections), Discussion (5 subsections)
- **Tables:** 2 (RRS main table, dual priority table)
- **Figures:** 1 (TOC graphic in Graphics/)
- **Compilation:** ✅ 0 errors, 0 undefined references

### Supporting Information
- **File:** `P1_V7_Integrated_Polypharmacology_RRS_SM.pdf`
- **Pages:** 17 (+4 from initial V7 version due to S10 addition)
- **Size:** 524 KB
- **Sections:** 12 (S1-S12)
  - S1: Cohort and evidence boundaries
  - S2: Chemical-space coverage
  - S3: Target-anchored docking matrix (Table + Figure)
  - S4: Physicochemical properties table
  - S5: Drug-likeness compliance table
  - S6: ADMET profile summary table
  - S7: RRS definition and class summary
  - S8: Exploratory cross-metric analysis
  - S9: Target evidence classes and limitations
  - **S10: Multi-parameter optimization framework (NEW)** ✨
  - S11: Reproducibility and availability
  - S12: Docking validation and protocol assessment (3 tables)
- **Tables:** 9
- **Figures:** 2
- **Compilation:** ✅ 0 errors, 0 undefined references

---

## SM Section S10 Details (New Addition)

### Content Overview

**Section Title:** "Multi-parameter optimization framework for upstream candidate selection"

**Introduction (~150 words):**
- Documents Set-C selection from MPO ≥ 0.40 optimization-worthy tier
- Cross-references companion manuscript for full validation
- Maintains V7's cautious framing: "computational prioritization evidence"

**Subsection S10.1: MPO scoring components**

Seven mathematical equations with full LaTeX formatting:

1. **Total MPO equation:**
   ```latex
   MPO_total = Σ(w_k · S_k) + Polypharmacology Bonus
   ```

2. **Vina affinity (35% weight):**
   ```latex
   S_vina = (Vina - Vina_min) / (Vina_max - Vina_min)
   ```
   Min-max scaling, more negative = higher desirability

3. **DiffDock confidence (25% weight):** ✨
   ```latex
   S_diff = 1 / (1 + e^(-c))
   ```
   Logistic sigmoid transformation, high-confidence (c > 0) → 1.0

4. **QED drug-likeness (20% weight):**
   ```latex
   S_qed = QED
   ```
   Direct use, no transformation

5. **ADMET composite (15% weight):**
   ```latex
   S_admet = (1/11) Σ d_m(ADMET_m)
   ```
   Average of 11 endpoints (HIA, solubility, Caco-2, BBB, hERG, AMES, DILI, SA, P-gp, CYP, clearance)

6. **Lipinski penalty (5% weight):**
   ```latex
   P_Ro5 = 1 - 0.2 · n_violations
   ```
   Proportional to violations (0-4): 0 violations = 1.0, 1 = 0.8, 2 = 0.6, 3 = 0.4, 4 = 0.2

7. **Polypharmacology bonus:**
   ```latex
   Bonus = 0.05 · (n_targets - 1)  if n_targets ≥ 2
   ```
   +0.05 per additional target, capped at +0.10 (3 targets)

**Subsection S10.2: Weight rationale and scope**

- Justification for 35/25/20/15/5 weight split
- Combined 60% docking weight reflects "central role of target engagement"
- Scope limitations: "served as upstream filter, does not validate Set-C quality"
- Cross-reference to companion manuscript:
  - Centroid workflow: 484 → 76 → 53 → 19,913
  - Sensitivity: 25 perturbations, Spearman ρ = 0.792
  - Validation: DEKOIS, MMV Malaria Box enrichment

---

## V7 Enhancements Summary (vs V6)

### 1. Comprehensive Validation Documentation (+3 pages)
- DEKOIS 2.0 external benchmark (ROC-AUC 0.450)
- MMV Malaria Box enrichment (ROC-AUC 0.924-1.000)
- Redocking validation (4/5 success, 80%)
- SM Section S12 with 3 tables

### 2. MPO and DiffDock Framework (+~1.5 pages) ✨ NEW
- 7 mathematical equations
- Component weight rationale
- **DiffDock confidence sigmoid formula explicitly documented**
- Set-C selection criterion (MPO ≥ 0.40)
- SM Section S10

### 3. Enhanced Physicochemical Characterization (+3 tables)
- Physicochemical properties (SM S4)
- Drug-likeness compliance (SM S5)
- ADMET profile summary (SM S6)

### 4. Improved Narrative Quality
- Results: 6 subsections, scientific prose (not report style)
- Discussion: expanded +125% (533 → ~1200 words)
- Anti-AI patterns eliminated throughout

### 5. Enhanced Methodological Rigor
- Grid box specifications for all 4 targets
- Computational efficiency documented (99.3% cost reduction)
- Enhanced cross-references main ↔ SM

---

## Submission Package Status

### Directory: `submission_ACS_P1V7/`

**Core Files (Updated 2026-01-11 19:56):**
- ✅ `P1_V7_Integrated_Polypharmacology_RRS.pdf` (449 KB, 25 pages)
- ✅ `P1_V7_Integrated_Polypharmacology_RRS_SM.pdf` (524 KB, 17 pages)
- ✅ `P1_V7_Integrated_Polypharmacology_RRS.bbl` (13 KB, main bibliography)
- ✅ `P1_V7_Integrated_Polypharmacology_RRS_SM.bbl` (6 KB, SM bibliography)
- ✅ `Cover_Letter_P1_V7.pdf` (142 KB, 2 pages - **refined 19:56**)
- ✅ `Sao_Chim_Space.bib` (74 KB, ~270 entries)

**Auxiliary Files:**
- ✅ `.aux` files (cross-references)
- ✅ Figures (TOC graphic, SM figures)

**Documentation:**
- ✅ `SUBMISSION_MANIFEST_V7.md` (v1.1, updated 2026-01-11 19:30)
- ✅ `PRE_SUBMISSION_INSTRUCTIONS.md`
- ✅ `ORCID_SUBMISSION_INSTRUCTIONS.md`
- ✅ `QUICK_START_NEXT_SESSION.md`
- ✅ `V7_COVER_LETTER_REFINEMENT.md` (refinement summary, 19:56)

---

## Pre-Submission Checklist

### Technical Requirements
- [x] Main PDF compiled (25 pages, 0 errors)
- [x] SM PDF compiled (17 pages, 0 errors)
- [x] All cross-references working (main ↔ SM)
- [x] All citations resolved
- [x] Bibliography included (.bib file)
- [x] Auxiliary files included (.aux, .bbl)
- [x] Cover letter prepared (2 pages)
- [x] TOC graphic present

### Metadata Requirements
- [x] Title finalized
- [x] Running title defined
- [x] Keywords listed
- [x] 5 authors listed
- [x] **ORCID iDs for all 5 authors** ✅ **COMPLETE (21:00)**
  - Myke Vital Sao Temgoua: ✅ 0009-0004-5170-2309
  - Serge Guy Nana Engo: ✅ 0000-0002-7484-3508
  - Wilfred Fon Mbacham: ✅ 0000-0002-3934-3233
  - Jean-Pierre Tchapet Njafa: ✅ 0000-0002-1936-8353
  - Penabei Samafou: ✅ 0000-0002-9683-7678
- [x] Funding acknowledgment added ("No external funding was received")

### Content Verification
- [x] Abstract concise and complete
- [x] Introduction motivates study
- [x] Methods reproducible
- [x] Results presented clearly
- [x] Discussion interprets findings
- [x] All figures referenced
- [x] All tables formatted correctly
- [x] All equations numbered
- [x] Evidence boundary maintained throughout

---

## ORCID Status — ✅ COMPLETE

**All 5 ORCID iDs collected and verified (2026-01-11 21:00)**

| Author Name | ORCID iD |
|-------------|----------|
| **Myke Vital Sao Temgoua** *(Corresponding)* | 0009-0004-5170-2309 |
| **Serge Guy Nana Engo** | 0000-0002-7484-3508 |
| **Wilfred Fon Mbacham** | 0000-0002-3934-3233 |
| **Jean-Pierre Tchapet Njafa** | 0000-0002-1936-8353 |
| **Penabei Samafou** | 0000-0002-9683-7678 |

**Entry Location:** Paragon Plus web form during submission (NOT in LaTeX source - ACS standard)

**Reference:** See `ORCID_SUBMISSION_INSTRUCTIONS.md` for complete checklist

---

## Evidence Boundary Compliance

V7 maintains strict evidence boundary throughout all new content:

### Language Used:
✅ "computational prioritization evidence"  
✅ "does not validate Set-C quality"  
✅ "computational prioritization estimates, not experimental measurements"  
✅ "served as an upstream filter"  
✅ "were selected" (past tense, selection criterion)

### Language Avoided:
❌ "high-quality hits"  
❌ "validated leads"  
❌ "promising compounds" (without computational qualifier)  
❌ "optimized candidates" (without "optimization-worthy tier" context)  
❌ "proven activity"

---

## Next Actions

### ✅ All Pre-Submission Requirements Complete

No further preparation needed. Manuscript is ready for immediate submission.

### During Paragon Plus Submission:
1. Create account at https://paragonplus.acs.org/
2. Select "Journal of Chemical Information and Modeling (JCIM)"
3. Start new submission
4. Upload main PDF (`P1_V7_Integrated_Polypharmacology_RRS.pdf`)
5. Upload SM PDF (`P1_V7_Integrated_Polypharmacology_RRS_SM.pdf`)
6. Upload bibliography file (`Sao_Chim_Space.bib`)
7. Upload cover letter (`Cover_Letter_P1_V7.pdf`)
8. **Enter all 5 ORCID iDs in web form** (see table above)
9. Complete metadata fields (title, keywords, abstract)
10. Verify author affiliations and emails
11. Confirm funding statement ("No external funding was received")
12. Review and submit

### Post-Submission:
1. Monitor submission dashboard for editor assignment
2. Respond to any technical queries promptly
3. Prepare for potential reviewer requests

---

## File Locations

### Source Files (for future edits):
- **Main:** `manuscript/P1_V7_Integrated_Polypharmacology_RRS.tex`
- **SM:** `manuscript/P1_V7_Integrated_Polypharmacology_RRS_SM.tex`
- **Bibliography:** `manuscript/Sao_Chim_Space.bib`
- **Cover Letter:** `manuscript/Cover_Letter_P1_V7.tex`

### Submission Package:
- **Directory:** `submission_ACS_P1V7/`
- **Manifest:** `submission_ACS_P1V7/SUBMISSION_MANIFEST_V7.md`

### Documentation:
- **Session tracking:** `project-tracking.md`
- **Promotion summary:** `P1_V7_PROMOTION_SUMMARY.md`
- **MPO integration:** `V7_MPO_DIFFDOCK_INTEGRATION_COMPLETE.md`
- **Final status:** `V7_FINAL_STATUS_20260111.md` (this file)

### Git Repository:
- **GitHub:** https://github.com/NanaEngo/Malaria_codesV2
- **Branch:** main
- **Last commit:** Should include today's MPO/DiffDock integration

---

## Version History

| Version | Date | Status | Key Changes |
|---------|------|--------|-------------|
| V4 | July 2026 | Archive | Chemical space, 2F6I remediation complete |
| V5 | Aug 2026 | Archive | 4-target docking methodology |
| V6 | 10 Aug 2026 | Superseded | 19 p. main, 5 p. SM, integrated RRS |
| **V7** | **11 Jan 2026** | **CANONICAL** | **25 p. main, 17 p. SM, comprehensive validation + MPO framework** |

**V7 supersedes all previous versions.**

---

## Summary

**V7 is READY FOR JCIM SUBMISSION.**

All requirements complete:
- ✅ 0 compilation errors (main + SM)
- ✅ Comprehensive validation documented
- ✅ MPO and DiffDock framework mathematically specified
- ✅ Physicochemical characterization complete
- ✅ Enhanced narrative quality
- ✅ Evidence boundary maintained
- ✅ Submission package generated
- ✅ Cover letter prepared
- ✅ Funding acknowledgment added
- ✅ **All 5 ORCID iDs collected and verified**

**No remaining requirements - manuscript is SUBMISSION-READY.**

**The manuscript represents a complete, transparent, and scientifically rigorous computational analysis of African-natural-product-inspired antimalarial chemotypes with documented target breadth and mutation resilience.**

---

**Report Generated:** 2026-01-11 21:00  
**Prepared By:** Kiro AI  
**For:** Myke Vital Sao Temgoua (Corresponding Author)  
**Status:** ✅ **SUBMISSION-READY (ALL REQUIREMENTS COMPLETE)**
